|
Pharmaceutical
Manufacturer
letter of May
9, 2007
Department of Health & Human Services
Healthcare Systems Bureau
May
9,
2007
Dear Pharmaceutical Manufacturer:
The Office of Pharmacy
Affairs (OPA) within
the Healthcare Systems Bureau of the Health
Resources and Services Administration issued
a letter to pharmaceutical manufacturers
dated January 30, 2007, in which it stated
that “(M)anufacturers that have signed
pharmaceutical pricing agreements (PPAs)
must continue to calculate 340B ceiling
prices so that the calculated price continues
to reflect a reduction for any prompt payment
discounts.”
In this January
30, 2007, letter,
OPA requested comments
from interested
parties regarding
this policy. OPA
has reviewed the
comment letters,
and in light of
the comments received
and the long standing
practices of the
340B program, OPA
has determined
that the issues
raised require
more analysis and
consideration.
Accordingly, until
further notice,
manufacturers should
calculate their
ceiling prices
according to CMS
requirements.
OPA plans to continue
to give careful
consideration to
the implications
of changes to the
Average Manufacturer
Price calculation
and other potential
changes to the
340B Drug Pricing
Program.
OPA very much
appreciates your
continued participation
in the 340B Drug
Pricing Program
and looks forward
to working with
all involved parties
in this process.
| |
Sincerely, |
| |
|
| |
Jimmy R. Mitchell, R.Ph, MPH, MS
Director
Office of Pharmacy Affairs |
|
